A new review in Frontiers, titled "Beyond the blockade: unmet needs in systemic targeted atopic dermatitis therapy," argues that the growing arsenal of targeted systemic treatments for atopic dermatitis has solved part of the problem — and exposed the rest.

The title itself is the thesis. Dupilumab, tralokinumab, and the JAK inhibitor class have moved AD care well beyond broad immunosuppression. But "beyond the blockade" signals the authors' real subject: what happens when a cytokine-targeted or pathway-targeted agent does its job and the patient still isn't clear.

What counts as an unmet need?

The review frames the gap around patients on systemic targeted therapy who plateau short of complete skin clearance or sustained itch control. That's a population every clinic sees: responders, but not remitters. The paper's focus is systemic targeted therapy specifically — biologics and small molecules — rather than topical care or phototherapy, which narrows the question to what the newest drug classes can and cannot deliver.

"Unmet needs" in this context spans several dimensions the authors map out:

• Patients who respond partially and stall below clear or almost-clear skin
• Persistence of itch and sleep disruption even when visible inflammation improves
• Heterogeneity of response across the AD population
• Gaps in long-term safety and durability data for newer agents
• Questions about treat-to-target strategies and how to sequence or switch agents

Why "beyond the blockade" matters

The phrasing is doing real work. Most targeted AD therapies operate by blocking a specific cytokine pathway — IL-4/IL-13 signaling in the case of dupilumab and tralokinumab, or broader JAK-mediated signaling for the oral small molecules. The review's central point is that blockade alone doesn't exhaust the disease. Atopic dermatitis is heterogeneous, and shutting down one inflammatory axis leaves others, plus barrier dysfunction and neural itch signaling, largely untouched.

That has direct implications for how clinicians set expectations. A patient who achieves a large EASI reduction on a biologic may still report pruritus that limits sleep — an outcome that clears on a physician-scored endpoint but fails on the patient's own. Reviews like this one push the field to weigh patient-reported outcomes as seriously as clinician-measured ones.

What does this change for practice?

For now, nothing operational — this is a review, not a trial, and it introduces no new efficacy data or regulatory change. Its value is directional. It consolidates the case that the next phase of AD drug development will target:

• Itch pathways independent of type 2 inflammation
• Faster onset and higher rates of complete clearance
• Better-defined positioning of JAK inhibitors versus biologics
• Structural end-organ strategies, including barrier repair, alongside immunologic ones

For dermatologists, the practical takeaway is to document residual disease — persistent pruritus, sleep loss, quality-of-life scores — rather than stopping the workup at EASI or IGA improvement. Those residuals are exactly where the field's next trials will be designed.

The review lands at a moment when the systemic AD pipeline is crowded and competitive, which makes its argument timely: with multiple blockade strategies already approved, differentiation will come from treating what blockade misses. The paper positions itself as a map of that unfinished territory — and, implicitly, as a research agenda for the next five years of atopic dermatitis therapy.